The first few months represent an exceptional period, not the permanent pace
Tatlidede E, Sehirli O, Veliolu-Onc A, Cetinel S, Yeen BC, Yarat A, et al
Intrinsic clearance and half-life were calculated [2]
The peptide itself is not a controlled substance in Canada, so customs issues are relatively rare for personal research quantities, but awareness of potential delays helps with planning
R&D pipeline: where are we now and whats next Currently, GLP-1s have received regulatory approval from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of: T2D
they are opening unprecedented commercial opportunities for suppliers, CDMOs, and regulatory-savvy manufacturers alike